ANI Pharmaceuticals announced the launch of Kionex for Oral or Rectal use. Kionex Suspension is the only commercially available therapeutically equivalent to the reference listed drug SPS Suspension for Oral or Rectal use. U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3M, based on March 2024 moving annual total IQVIA data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Financial Health Overview Released
- ANI Pharmaceuticals price target raised to $87 from $83 at H.C. Wainwright
- ANI Pharmaceuticals sees 2024 adjusted EPS $4.26-$4.67, consensus $4.48
- ANI Pharmaceuticals reports Q1 adjusted EPS $1.21, consensus $1.00
- ANIP Upcoming Earnings Report: What to Expect?